期刊文献+

新型非典型抗精神病药:伊潘立酮 被引量:3

原文传递
导出
摘要 针对目前抗精神病药物依从性差、不能耐受和频繁换药等特点,开发更加安全有效的新型抗精神病药物成为一项具有挑战性任务。伊潘立酮作为一种新型非典型抗精神病药物,主要拮抗5-羟色胺2A受体(5-HT_(2A))和多巴胺-2受体(D_2),用于成人精神分裂症的治疗。就目前临床研究资料显示,该药安全有效,主要特点为锥体外系不良反应(EPS)少,代谢异常和体质量增加的发生率较低,但可引起QT间期延长和直立性低血压。
出处 《中国临床药学杂志》 CAS 2011年第5期318-322,共5页 Chinese Journal of Clinical Pharmacy
基金 科技重大专项"精神药物新药临床评价研究技术平台"(编号20082X09312-003)
  • 相关文献

参考文献24

  • 1Lieberman JA, Strenp TS, McEvoy JP, et al. Effectiveness of antipsychotic druss in patients with chronic schizophrenia[J]. N Engl J Med, 2005, 353(12): 1209.
  • 2Citrome L. lloperidone for schizoplurenia: a review of the efficacy and safety profile for this newly conunvrcialised second-generation antipsychotic[J]. Int J Clin Pract, 2009, 63(8) : 1237.
  • 3Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications[J]. Clin Phannacokinet, 2000, 38(5) : 393.
  • 4Kongssmut S, Roehr JE, Cai J, et al. noperidone binding to human and rat dopamine and 5-HT receptors[J]. Eur J Phannacol, 1996, 317 (2 - 3) :417.
  • 5Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders [ J ]. Neuropsyehophannacology, 2001,25 ( 6 ) : 904.
  • 6Caccia S, Pasinal L, Nobili A. New atypical antipsychotics for schizoprenia:iloperldone[J]. Drug Des Devel Ther, 2010, 18(3): 33.
  • 7Szczepanik AM, Brougham LR, Roehr JE, et al. Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotie with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity[J]. J Pharmacol Exp Ther, 1996,278(2) :913.
  • 8Strupczewski JT, Bonieau KJ, Chang Y, et al. 3-[(Aayloxy)alkyl] pipefidinyl-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsyehotie activity: anfipsyehotic profile of iloperidme(HP 873)[J]. J Med Chem, 1985,28(6):761.
  • 9Fanapt(iloperidone tablets)[ EB/OL]. http://www, rxlist.com/fanaptdrug.htm. [2011-01-21].
  • 10Sedek G, Wolfgang C. lloperidone is well tolerated by subjects with renal or hepatic impairment in single-dose clinical pharmacokinetics studies. 160th Annual Meeting of the American Psychiatric Association[C]. Washington, DC,2007,19 - 24:204.

同被引文献31

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部